Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 44 | 2024 | 17575 | 1.780 |
Why?
|
South Africa | 16 | 2024 | 1871 | 1.200 |
Why?
|
CD4 Lymphocyte Count | 12 | 2024 | 2596 | 0.990 |
Why?
|
Alendronate | 4 | 2005 | 174 | 0.700 |
Why?
|
Viral Load | 7 | 2024 | 3398 | 0.620 |
Why?
|
Beauty Culture | 1 | 2018 | 41 | 0.620 |
Why?
|
Anti-HIV Agents | 14 | 2024 | 4571 | 0.610 |
Why?
|
Speech Disorders | 1 | 2018 | 180 | 0.560 |
Why?
|
Contraception | 1 | 2018 | 362 | 0.480 |
Why?
|
Hair | 1 | 2018 | 507 | 0.480 |
Why?
|
Ambulatory Care Facilities | 4 | 2024 | 940 | 0.470 |
Why?
|
Constipation | 1 | 2018 | 570 | 0.430 |
Why?
|
Medication Adherence | 4 | 2024 | 2189 | 0.430 |
Why?
|
Estrogens, Conjugated (USP) | 2 | 2005 | 277 | 0.420 |
Why?
|
Tuberculosis, Pulmonary | 1 | 2019 | 845 | 0.400 |
Why?
|
Patient Transfer | 1 | 2019 | 793 | 0.390 |
Why?
|
Autistic Disorder | 4 | 2021 | 1240 | 0.360 |
Why?
|
Lamivudine | 6 | 2017 | 367 | 0.350 |
Why?
|
Hormone Replacement Therapy | 2 | 2005 | 756 | 0.330 |
Why?
|
Anxiety | 4 | 2024 | 4675 | 0.330 |
Why?
|
Feasibility Studies | 5 | 2024 | 5311 | 0.330 |
Why?
|
Osteoporosis, Postmenopausal | 4 | 2007 | 399 | 0.320 |
Why?
|
Anti-Retroviral Agents | 6 | 2022 | 1794 | 0.310 |
Why?
|
Health Knowledge, Attitudes, Practice | 3 | 2022 | 4047 | 0.310 |
Why?
|
Estrogen Replacement Therapy | 2 | 2005 | 1209 | 0.290 |
Why?
|
Decision Support Techniques | 1 | 2017 | 2005 | 0.290 |
Why?
|
Models, Theoretical | 2 | 2017 | 3579 | 0.270 |
Why?
|
Medroxyprogesterone | 1 | 2005 | 35 | 0.260 |
Why?
|
Tuberculosis | 1 | 2019 | 2029 | 0.260 |
Why?
|
Adult | 54 | 2024 | 223622 | 0.260 |
Why?
|
Female | 73 | 2025 | 397050 | 0.250 |
Why?
|
Hip | 2 | 2017 | 255 | 0.250 |
Why?
|
Cost-Benefit Analysis | 9 | 2018 | 5538 | 0.250 |
Why?
|
Refugees | 3 | 2020 | 612 | 0.240 |
Why?
|
Reverse Transcriptase Inhibitors | 4 | 2017 | 622 | 0.240 |
Why?
|
Bone Density | 6 | 2017 | 3559 | 0.230 |
Why?
|
Antiretroviral Therapy, Highly Active | 6 | 2024 | 1903 | 0.230 |
Why?
|
Humans | 94 | 2025 | 768298 | 0.220 |
Why?
|
Benzoxazines | 4 | 2017 | 321 | 0.220 |
Why?
|
Progesterone Congeners | 1 | 2003 | 44 | 0.220 |
Why?
|
Pancreatitis | 2 | 2013 | 1087 | 0.210 |
Why?
|
Male | 63 | 2025 | 364870 | 0.210 |
Why?
|
Penicillins | 2 | 2016 | 406 | 0.200 |
Why?
|
Medroxyprogesterone Acetate | 1 | 2003 | 156 | 0.200 |
Why?
|
Brain Concussion | 2 | 2024 | 1433 | 0.200 |
Why?
|
Trichomonas Infections | 1 | 2022 | 41 | 0.200 |
Why?
|
Drug Monitoring | 2 | 2018 | 964 | 0.190 |
Why?
|
HIV-1 | 8 | 2020 | 6963 | 0.190 |
Why?
|
Stavudine | 5 | 2008 | 85 | 0.190 |
Why?
|
Alkynes | 4 | 2017 | 327 | 0.190 |
Why?
|
Bone Remodeling | 1 | 2005 | 583 | 0.190 |
Why?
|
Radiographic Image Enhancement | 3 | 2015 | 877 | 0.180 |
Why?
|
Forecasting | 2 | 2020 | 2948 | 0.180 |
Why?
|
Placebos | 3 | 2019 | 1668 | 0.180 |
Why?
|
Cyclopropanes | 4 | 2017 | 437 | 0.180 |
Why?
|
Acquired Immunodeficiency Syndrome | 2 | 2006 | 2202 | 0.170 |
Why?
|
Didanosine | 4 | 2007 | 151 | 0.170 |
Why?
|
Positive-Pressure Respiration | 2 | 2023 | 713 | 0.160 |
Why?
|
Life Expectancy | 2 | 2016 | 1249 | 0.160 |
Why?
|
Models, Economic | 3 | 2018 | 718 | 0.160 |
Why?
|
Pregnancy, Unwanted | 1 | 2018 | 24 | 0.160 |
Why?
|
Bacteremia | 2 | 2016 | 985 | 0.160 |
Why?
|
Motor Activity | 2 | 2005 | 2720 | 0.160 |
Why?
|
Nelfinavir | 3 | 2007 | 68 | 0.150 |
Why?
|
Chlamydia Infections | 1 | 2022 | 365 | 0.150 |
Why?
|
Clinical Trials as Topic | 3 | 2018 | 8051 | 0.150 |
Why?
|
Pica | 1 | 2018 | 37 | 0.150 |
Why?
|
Community Health Services | 2 | 2020 | 659 | 0.150 |
Why?
|
Family Characteristics | 1 | 2023 | 1003 | 0.150 |
Why?
|
Child Health Services | 2 | 2020 | 645 | 0.150 |
Why?
|
Gonorrhea | 1 | 2022 | 355 | 0.140 |
Why?
|
Dental Care | 1 | 2020 | 286 | 0.140 |
Why?
|
Data Interpretation, Statistical | 1 | 2007 | 2708 | 0.140 |
Why?
|
Psychomotor Performance | 1 | 2005 | 1895 | 0.140 |
Why?
|
Diazoxide | 3 | 2007 | 52 | 0.140 |
Why?
|
Cohort Studies | 10 | 2024 | 41791 | 0.140 |
Why?
|
Muscle Hypotonia | 1 | 2018 | 166 | 0.140 |
Why?
|
Middle Aged | 36 | 2025 | 223463 | 0.140 |
Why?
|
Dideoxynucleosides | 1 | 2017 | 135 | 0.140 |
Why?
|
Drug Hypersensitivity | 2 | 2016 | 923 | 0.140 |
Why?
|
Staphylococcal Infections | 2 | 2016 | 1398 | 0.140 |
Why?
|
Attention Deficit and Disruptive Behavior Disorders | 1 | 2018 | 305 | 0.130 |
Why?
|
Algorithms | 4 | 2019 | 14154 | 0.130 |
Why?
|
Proportional Hazards Models | 3 | 2020 | 12557 | 0.130 |
Why?
|
Intraoperative Care | 1 | 2020 | 771 | 0.130 |
Why?
|
Cardioplegic Solutions | 2 | 2007 | 123 | 0.130 |
Why?
|
Sputum | 1 | 2019 | 511 | 0.130 |
Why?
|
Pain Measurement | 2 | 2024 | 3579 | 0.130 |
Why?
|
Respiratory Mechanics | 1 | 2020 | 722 | 0.130 |
Why?
|
Treatment Failure | 2 | 2017 | 2664 | 0.130 |
Why?
|
Sexually Transmitted Diseases | 1 | 2022 | 666 | 0.130 |
Why?
|
Eczema | 1 | 2018 | 245 | 0.130 |
Why?
|
Absorptiometry, Photon | 4 | 2017 | 1752 | 0.130 |
Why?
|
Pilot Projects | 8 | 2025 | 8730 | 0.130 |
Why?
|
HIV | 4 | 2018 | 1596 | 0.130 |
Why?
|
Cross-Sectional Studies | 7 | 2022 | 26373 | 0.120 |
Why?
|
Probiotics | 1 | 2019 | 383 | 0.120 |
Why?
|
Vitamin D Deficiency | 1 | 2005 | 1389 | 0.120 |
Why?
|
Educational Status | 1 | 2023 | 2518 | 0.120 |
Why?
|
Public Sector | 1 | 2017 | 266 | 0.120 |
Why?
|
Mass Screening | 4 | 2021 | 5451 | 0.120 |
Why?
|
Indinavir | 2 | 2005 | 73 | 0.120 |
Why?
|
Smoking Cessation | 2 | 2017 | 2083 | 0.120 |
Why?
|
Employee Performance Appraisal | 1 | 2015 | 86 | 0.120 |
Why?
|
Financing, Personal | 1 | 2017 | 310 | 0.120 |
Why?
|
Random Allocation | 1 | 2019 | 2397 | 0.120 |
Why?
|
Drug Substitution | 1 | 2017 | 291 | 0.120 |
Why?
|
Influenza Vaccines | 1 | 2022 | 780 | 0.120 |
Why?
|
Vitamin D | 2 | 2005 | 3311 | 0.120 |
Why?
|
Young Adult | 12 | 2024 | 60048 | 0.120 |
Why?
|
Caregivers | 2 | 2025 | 2303 | 0.120 |
Why?
|
Income | 1 | 2023 | 1877 | 0.110 |
Why?
|
Abdomen | 1 | 2020 | 1136 | 0.110 |
Why?
|
Needs Assessment | 1 | 2020 | 1142 | 0.110 |
Why?
|
HIV Integrase Inhibitors | 1 | 2015 | 165 | 0.110 |
Why?
|
Prevalence | 6 | 2022 | 15868 | 0.110 |
Why?
|
AIDS Serodiagnosis | 1 | 2014 | 220 | 0.110 |
Why?
|
Social Support | 2 | 2020 | 2190 | 0.110 |
Why?
|
Zidovudine | 4 | 2008 | 625 | 0.110 |
Why?
|
Myocardial Reperfusion Injury | 3 | 2007 | 484 | 0.110 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2015 | 295 | 0.110 |
Why?
|
Adolescent | 13 | 2024 | 89182 | 0.100 |
Why?
|
Heart Arrest | 1 | 2023 | 1516 | 0.100 |
Why?
|
Lung Diseases | 1 | 2023 | 1925 | 0.100 |
Why?
|
Models, Statistical | 4 | 2019 | 5099 | 0.100 |
Why?
|
Tomography, Spiral Computed | 1 | 2014 | 274 | 0.100 |
Why?
|
Drug Combinations | 2 | 2017 | 2078 | 0.100 |
Why?
|
Double-Blind Method | 6 | 2007 | 12457 | 0.100 |
Why?
|
Internationality | 1 | 2018 | 1008 | 0.100 |
Why?
|
Indomethacin | 1 | 2013 | 323 | 0.100 |
Why?
|
Dietary Supplements | 1 | 2005 | 3443 | 0.100 |
Why?
|
Models, Educational | 1 | 2015 | 375 | 0.100 |
Why?
|
Health Services Needs and Demand | 1 | 2020 | 1406 | 0.100 |
Why?
|
Anesthesia | 1 | 2023 | 1596 | 0.100 |
Why?
|
Research Design | 1 | 2007 | 6209 | 0.090 |
Why?
|
Aged | 27 | 2025 | 171544 | 0.090 |
Why?
|
United States | 14 | 2021 | 73144 | 0.090 |
Why?
|
Aging | 4 | 2020 | 8764 | 0.090 |
Why?
|
Prospective Studies | 14 | 2023 | 54921 | 0.090 |
Why?
|
Mind-Body Therapies | 2 | 2024 | 291 | 0.090 |
Why?
|
Influenza, Human | 1 | 2022 | 1539 | 0.090 |
Why?
|
Health Care Costs | 3 | 2018 | 3267 | 0.090 |
Why?
|
Drugs, Generic | 1 | 2015 | 454 | 0.090 |
Why?
|
Radiography, Dual-Energy Scanned Projection | 1 | 2013 | 204 | 0.090 |
Why?
|
Computer Simulation | 3 | 2019 | 6277 | 0.090 |
Why?
|
Research Support as Topic | 1 | 2015 | 696 | 0.090 |
Why?
|
Self Report | 2 | 2024 | 3766 | 0.090 |
Why?
|
Smoking | 2 | 2017 | 9109 | 0.090 |
Why?
|
Dementia | 1 | 2025 | 2728 | 0.090 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 2 | 2014 | 1226 | 0.080 |
Why?
|
Depression | 2 | 2021 | 8241 | 0.080 |
Why?
|
Cholangiopancreatography, Endoscopic Retrograde | 1 | 2013 | 520 | 0.080 |
Why?
|
Homosexuality, Male | 1 | 2018 | 1345 | 0.080 |
Why?
|
Continuity of Patient Care | 1 | 2017 | 1076 | 0.080 |
Why?
|
Developmental Disabilities | 1 | 2018 | 1516 | 0.080 |
Why?
|
Treatment Outcome | 12 | 2024 | 65365 | 0.080 |
Why?
|
Drug Therapy, Combination | 5 | 2007 | 6319 | 0.080 |
Why?
|
Primary Health Care | 3 | 2021 | 4748 | 0.080 |
Why?
|
HIV Protease Inhibitors | 3 | 2008 | 432 | 0.080 |
Why?
|
Oxazines | 2 | 2015 | 357 | 0.080 |
Why?
|
Contrast Media | 4 | 2015 | 5337 | 0.080 |
Why?
|
Body Composition | 3 | 2007 | 2461 | 0.080 |
Why?
|
Family | 1 | 2020 | 3208 | 0.080 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2014 | 736 | 0.080 |
Why?
|
RNA, Viral | 1 | 2017 | 2866 | 0.080 |
Why?
|
Infant | 3 | 2020 | 36512 | 0.080 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 1 | 2015 | 703 | 0.080 |
Why?
|
Point-of-Care Systems | 1 | 2017 | 1238 | 0.080 |
Why?
|
Uganda | 3 | 2020 | 1351 | 0.080 |
Why?
|
Anti-Bacterial Agents | 3 | 2016 | 7458 | 0.080 |
Why?
|
Cooperative Behavior | 1 | 2015 | 1515 | 0.080 |
Why?
|
Staphylococcus aureus | 1 | 2016 | 1428 | 0.070 |
Why?
|
Academic Medical Centers | 2 | 2015 | 2783 | 0.070 |
Why?
|
Osteocalcin | 2 | 2007 | 277 | 0.070 |
Why?
|
Mortality | 1 | 2019 | 2917 | 0.070 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2020 | 4411 | 0.070 |
Why?
|
Geranyltranstransferase | 1 | 2007 | 5 | 0.070 |
Why?
|
Time Factors | 11 | 2020 | 40267 | 0.070 |
Why?
|
Faculty, Medical | 1 | 2015 | 1218 | 0.070 |
Why?
|
Research | 1 | 2015 | 1981 | 0.070 |
Why?
|
Radiation Injuries | 1 | 2014 | 1204 | 0.070 |
Why?
|
Trust | 2 | 2022 | 532 | 0.070 |
Why?
|
Child | 9 | 2021 | 80894 | 0.070 |
Why?
|
Vascular Diseases | 1 | 2015 | 1161 | 0.070 |
Why?
|
Isotonic Solutions | 1 | 2006 | 120 | 0.070 |
Why?
|
Program Evaluation | 1 | 2015 | 2505 | 0.070 |
Why?
|
Testosterone | 2 | 2007 | 2493 | 0.060 |
Why?
|
Health Services Accessibility | 2 | 2020 | 5511 | 0.060 |
Why?
|
Delivery of Health Care | 2 | 2020 | 5375 | 0.060 |
Why?
|
Pregnancy | 4 | 2022 | 30198 | 0.060 |
Why?
|
Socioeconomic Factors | 1 | 2019 | 7861 | 0.060 |
Why?
|
Alkaline Phosphatase | 2 | 2007 | 864 | 0.060 |
Why?
|
Body Fat Distribution | 1 | 2006 | 246 | 0.060 |
Why?
|
Nucleosides | 1 | 2005 | 131 | 0.060 |
Why?
|
Densitometry | 1 | 2005 | 151 | 0.060 |
Why?
|
Collagen Type I | 2 | 2007 | 620 | 0.060 |
Why?
|
Anti-Infective Agents, Local | 1 | 2007 | 248 | 0.060 |
Why?
|
Abdominal Fat | 1 | 2006 | 221 | 0.060 |
Why?
|
Pediatrics | 1 | 2020 | 3624 | 0.060 |
Why?
|
Canada | 2 | 2020 | 2139 | 0.060 |
Why?
|
Bone and Bones | 2 | 2005 | 2588 | 0.060 |
Why?
|
Hydroxyurea | 1 | 2005 | 284 | 0.060 |
Why?
|
Lactates | 1 | 2005 | 401 | 0.060 |
Why?
|
Hyperinsulinism | 1 | 2007 | 401 | 0.060 |
Why?
|
Minerals | 1 | 2005 | 282 | 0.060 |
Why?
|
Thiazolidinediones | 1 | 2007 | 461 | 0.050 |
Why?
|
Kidney Neoplasms | 2 | 2014 | 4301 | 0.050 |
Why?
|
Interleukin-2 | 3 | 2005 | 1894 | 0.050 |
Why?
|
Kidney | 3 | 2014 | 7063 | 0.050 |
Why?
|
Comorbidity | 1 | 2018 | 10588 | 0.050 |
Why?
|
HN Protein | 1 | 2003 | 8 | 0.050 |
Why?
|
Drug Administration Schedule | 4 | 2020 | 4859 | 0.050 |
Why?
|
Blood Specimen Collection | 1 | 2005 | 238 | 0.050 |
Why?
|
Femur Neck | 1 | 2005 | 318 | 0.050 |
Why?
|
Cardiotonic Agents | 1 | 2006 | 544 | 0.050 |
Why?
|
Cholinergic Fibers | 1 | 2003 | 69 | 0.050 |
Why?
|
Lung Neoplasms | 2 | 2018 | 13576 | 0.050 |
Why?
|
Macaca fascicularis | 1 | 2005 | 913 | 0.050 |
Why?
|
Calcium | 2 | 2007 | 5794 | 0.050 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 2018 | 3743 | 0.050 |
Why?
|
Melanoma | 3 | 2010 | 5705 | 0.050 |
Why?
|
Epilepsy | 1 | 2018 | 3326 | 0.050 |
Why?
|
Carotid Artery Thrombosis | 1 | 2002 | 50 | 0.050 |
Why?
|
Schools | 2 | 2023 | 1496 | 0.050 |
Why?
|
Pulmonary Eosinophilia | 1 | 2003 | 78 | 0.050 |
Why?
|
Paclitaxel | 1 | 2010 | 1736 | 0.050 |
Why?
|
Telemedicine | 1 | 2020 | 3107 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2024 | 10377 | 0.050 |
Why?
|
Quality of Life | 2 | 2025 | 13499 | 0.050 |
Why?
|
Respiratory Syncytial Viruses | 1 | 2003 | 168 | 0.050 |
Why?
|
Child, Preschool | 3 | 2020 | 42654 | 0.050 |
Why?
|
Tomography, X-Ray Computed | 3 | 2014 | 20766 | 0.050 |
Why?
|
Aged, 80 and over | 9 | 2018 | 59683 | 0.050 |
Why?
|
Post-Concussion Syndrome | 1 | 2024 | 256 | 0.050 |
Why?
|
Postoperative Complications | 2 | 2023 | 15854 | 0.050 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2005 | 794 | 0.050 |
Why?
|
Albuminuria | 1 | 2005 | 658 | 0.050 |
Why?
|
Multicenter Studies as Topic | 2 | 2023 | 1727 | 0.050 |
Why?
|
Mitochondria, Heart | 1 | 2002 | 236 | 0.050 |
Why?
|
Risk Factors | 11 | 2019 | 74954 | 0.050 |
Why?
|
Postural Balance | 1 | 2005 | 639 | 0.050 |
Why?
|
Prosencephalon | 1 | 2003 | 306 | 0.050 |
Why?
|
Stents | 1 | 2013 | 3201 | 0.050 |
Why?
|
Colonic Diseases, Functional | 1 | 2000 | 39 | 0.040 |
Why?
|
Area Under Curve | 1 | 2005 | 1642 | 0.040 |
Why?
|
Body Weight | 3 | 2006 | 4630 | 0.040 |
Why?
|
Interleukin-13 | 1 | 2003 | 391 | 0.040 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2010 | 11854 | 0.040 |
Why?
|
Oxygen Consumption | 1 | 2007 | 1882 | 0.040 |
Why?
|
Diphosphonates | 1 | 2005 | 635 | 0.040 |
Why?
|
Sulfonamides | 1 | 2010 | 1980 | 0.040 |
Why?
|
Dehydroepiandrosterone | 1 | 2021 | 259 | 0.040 |
Why?
|
Specimen Handling | 1 | 2005 | 707 | 0.040 |
Why?
|
Simian immunodeficiency virus | 1 | 2005 | 814 | 0.040 |
Why?
|
Stroke | 2 | 2018 | 9742 | 0.040 |
Why?
|
Biomarkers, Pharmacological | 1 | 2020 | 162 | 0.040 |
Why?
|
Dacarbazine | 1 | 2002 | 560 | 0.040 |
Why?
|
Pyrazoles | 1 | 2010 | 2021 | 0.040 |
Why?
|
Africa South of the Sahara | 1 | 2022 | 751 | 0.040 |
Why?
|
Biomedical Research | 1 | 2015 | 3464 | 0.040 |
Why?
|
Carcinoma, Renal Cell | 2 | 2005 | 3199 | 0.040 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2019 | 12239 | 0.040 |
Why?
|
Head and Neck Neoplasms | 1 | 2013 | 2923 | 0.040 |
Why?
|
Metformin | 1 | 2007 | 911 | 0.040 |
Why?
|
Infarction, Middle Cerebral Artery | 1 | 2002 | 485 | 0.040 |
Why?
|
Hypertension | 1 | 2019 | 8615 | 0.040 |
Why?
|
Femur | 1 | 2005 | 1311 | 0.040 |
Why?
|
Macaca mulatta | 1 | 2005 | 2361 | 0.040 |
Why?
|
Observer Variation | 2 | 2015 | 2623 | 0.040 |
Why?
|
Estrogens | 1 | 2005 | 1534 | 0.040 |
Why?
|
Walking | 1 | 2005 | 1201 | 0.040 |
Why?
|
Bone Density Conservation Agents | 1 | 2005 | 797 | 0.040 |
Why?
|
Case Management | 1 | 2020 | 276 | 0.040 |
Why?
|
Respiratory Syncytial Virus Infections | 1 | 2003 | 365 | 0.040 |
Why?
|
Mozambique | 1 | 2017 | 55 | 0.040 |
Why?
|
Pituitary-Adrenal System | 1 | 2021 | 557 | 0.040 |
Why?
|
Accidental Falls | 1 | 2005 | 1080 | 0.040 |
Why?
|
Statistics, Nonparametric | 2 | 2017 | 2862 | 0.040 |
Why?
|
Skin Neoplasms | 2 | 2010 | 5857 | 0.040 |
Why?
|
Universities | 1 | 2023 | 1005 | 0.040 |
Why?
|
Reproducibility of Results | 4 | 2019 | 20224 | 0.040 |
Why?
|
Rural Population | 2 | 2018 | 2318 | 0.040 |
Why?
|
Adipose Tissue | 2 | 2006 | 3334 | 0.030 |
Why?
|
Fentanyl | 1 | 2000 | 450 | 0.030 |
Why?
|
Hypothalamo-Hypophyseal System | 1 | 2021 | 705 | 0.030 |
Why?
|
Resilience, Psychological | 1 | 2025 | 804 | 0.030 |
Why?
|
North America | 1 | 2020 | 1290 | 0.030 |
Why?
|
Collagen | 1 | 2005 | 2646 | 0.030 |
Why?
|
Tissue Plasminogen Activator | 1 | 2002 | 1163 | 0.030 |
Why?
|
Insurance, Health, Reimbursement | 1 | 2020 | 390 | 0.030 |
Why?
|
Methicillin | 1 | 2016 | 62 | 0.030 |
Why?
|
Pain Threshold | 1 | 2000 | 606 | 0.030 |
Why?
|
Activities of Daily Living | 1 | 2005 | 2433 | 0.030 |
Why?
|
Endothelium, Vascular | 1 | 2008 | 4427 | 0.030 |
Why?
|
Boston | 2 | 2007 | 9371 | 0.030 |
Why?
|
Regression Analysis | 3 | 2016 | 6350 | 0.030 |
Why?
|
Postmenopause | 1 | 2005 | 2518 | 0.030 |
Why?
|
Appointments and Schedules | 1 | 2020 | 442 | 0.030 |
Why?
|
Demography | 2 | 2015 | 1642 | 0.030 |
Why?
|
Sex Characteristics | 1 | 2006 | 2661 | 0.030 |
Why?
|
Kenya | 1 | 2018 | 757 | 0.030 |
Why?
|
Myocardial Ischemia | 1 | 2006 | 2139 | 0.030 |
Why?
|
HIV-Associated Lipodystrophy Syndrome | 2 | 2007 | 138 | 0.030 |
Why?
|
Brachiocephalic Veins | 1 | 2015 | 21 | 0.030 |
Why?
|
Subclavian Vein | 1 | 2015 | 57 | 0.030 |
Why?
|
Forearm | 1 | 2017 | 428 | 0.030 |
Why?
|
Attitude | 1 | 2020 | 772 | 0.030 |
Why?
|
Voluntary Programs | 1 | 2014 | 48 | 0.030 |
Why?
|
beta-Lactams | 1 | 2016 | 158 | 0.030 |
Why?
|
Iopamidol | 1 | 2015 | 187 | 0.030 |
Why?
|
Blood Circulation | 1 | 2015 | 248 | 0.030 |
Why?
|
Skin Tests | 1 | 2016 | 639 | 0.030 |
Why?
|
Michigan | 1 | 2015 | 341 | 0.030 |
Why?
|
Hypoglycemic Agents | 1 | 2007 | 3108 | 0.030 |
Why?
|
Registries | 2 | 2020 | 8378 | 0.030 |
Why?
|
Phlebography | 1 | 2015 | 326 | 0.030 |
Why?
|
Blood Glucose | 2 | 2005 | 6430 | 0.030 |
Why?
|
Jugular Veins | 1 | 2015 | 211 | 0.030 |
Why?
|
Health Resources | 1 | 2020 | 950 | 0.030 |
Why?
|
Obesity | 3 | 2021 | 13082 | 0.030 |
Why?
|
Mitochondria | 1 | 2007 | 3675 | 0.030 |
Why?
|
Tanzania | 1 | 2018 | 1403 | 0.030 |
Why?
|
Administration, Rectal | 1 | 2013 | 69 | 0.030 |
Why?
|
Vancomycin | 1 | 2016 | 504 | 0.030 |
Why?
|
Budgets | 1 | 2015 | 232 | 0.030 |
Why?
|
Biostatistics | 1 | 2015 | 165 | 0.030 |
Why?
|
Hydrocortisone | 1 | 2021 | 1841 | 0.030 |
Why?
|
Clinical Laboratory Techniques | 1 | 2018 | 749 | 0.030 |
Why?
|
Clinical Competence | 2 | 2020 | 4847 | 0.030 |
Why?
|
Sex Factors | 1 | 2007 | 10656 | 0.030 |
Why?
|
Writing | 1 | 2015 | 200 | 0.030 |
Why?
|
Peptides | 1 | 2005 | 4352 | 0.030 |
Why?
|
C-Reactive Protein | 1 | 2004 | 3859 | 0.030 |
Why?
|
Incidence | 2 | 2015 | 21544 | 0.030 |
Why?
|
Insulin Resistance | 2 | 2005 | 3981 | 0.030 |
Why?
|
Age Factors | 2 | 2007 | 18472 | 0.030 |
Why?
|
Retrospective Studies | 7 | 2016 | 81768 | 0.030 |
Why?
|
Authorship | 1 | 2015 | 289 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2020 | 2353 | 0.020 |
Why?
|
Survivors | 1 | 2023 | 2382 | 0.020 |
Why?
|
Faculty | 1 | 2015 | 384 | 0.020 |
Why?
|
Pandemics | 2 | 2022 | 8750 | 0.020 |
Why?
|
Kidney Function Tests | 1 | 2014 | 681 | 0.020 |
Why?
|
Radiation Tolerance | 1 | 2014 | 478 | 0.020 |
Why?
|
Delayed-Action Preparations | 1 | 2015 | 968 | 0.020 |
Why?
|
Brazil | 1 | 2016 | 1247 | 0.020 |
Why?
|
Anxiety Disorders | 1 | 2023 | 2754 | 0.020 |
Why?
|
Wounds and Injuries | 1 | 2024 | 2513 | 0.020 |
Why?
|
Subtraction Technique | 1 | 2014 | 519 | 0.020 |
Why?
|
Early Diagnosis | 1 | 2016 | 1195 | 0.020 |
Why?
|
Lipids | 3 | 2007 | 3344 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2018 | 1735 | 0.020 |
Why?
|
Feedback | 1 | 2015 | 795 | 0.020 |
Why?
|
Spine | 1 | 2017 | 1141 | 0.020 |
Why?
|
Pyridones | 1 | 2015 | 818 | 0.020 |
Why?
|
Rabbits | 2 | 2007 | 4782 | 0.020 |
Why?
|
Eosinophils | 1 | 2015 | 953 | 0.020 |
Why?
|
Vaccination | 1 | 2022 | 3431 | 0.020 |
Why?
|
Microbial Sensitivity Tests | 1 | 2016 | 1955 | 0.020 |
Why?
|
Immunotherapy | 1 | 2005 | 4740 | 0.020 |
Why?
|
Urban Population | 1 | 2017 | 2045 | 0.020 |
Why?
|
Risk | 2 | 2015 | 9635 | 0.020 |
Why?
|
Pulmonary Veins | 1 | 2015 | 754 | 0.020 |
Why?
|
Heart Atria | 1 | 2015 | 1360 | 0.020 |
Why?
|
Patient Acceptance of Health Care | 1 | 2022 | 3230 | 0.020 |
Why?
|
Tumor Burden | 1 | 2014 | 1913 | 0.020 |
Why?
|
Cognition | 1 | 2005 | 7074 | 0.020 |
Why?
|
Teaching | 1 | 2015 | 1172 | 0.020 |
Why?
|
Heart Ventricles | 2 | 2015 | 3838 | 0.020 |
Why?
|
Recovery of Function | 1 | 2018 | 2990 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2005 | 10266 | 0.020 |
Why?
|
Lung | 2 | 2023 | 10087 | 0.020 |
Why?
|
Drug Costs | 1 | 2015 | 1196 | 0.020 |
Why?
|
Allergens | 1 | 2015 | 1445 | 0.020 |
Why?
|
Health Personnel | 1 | 2021 | 3381 | 0.020 |
Why?
|
Triage | 1 | 2014 | 994 | 0.020 |
Why?
|
Neoplasm Metastasis | 2 | 2010 | 4921 | 0.020 |
Why?
|
Brachial Artery | 1 | 2008 | 373 | 0.020 |
Why?
|
Apoptosis | 1 | 2002 | 9506 | 0.020 |
Why?
|
Ritonavir | 1 | 2008 | 330 | 0.020 |
Why?
|
Communication | 1 | 2020 | 3912 | 0.020 |
Why?
|
Parents | 1 | 2020 | 3596 | 0.020 |
Why?
|
Artifacts | 1 | 2015 | 1930 | 0.020 |
Why?
|
Pulmonary Artery | 1 | 2015 | 1945 | 0.020 |
Why?
|
Pyrimidinones | 1 | 2008 | 386 | 0.020 |
Why?
|
Decision Support Systems, Clinical | 1 | 2015 | 1177 | 0.020 |
Why?
|
Myocardial Reperfusion | 1 | 2007 | 339 | 0.020 |
Why?
|
Waist-Hip Ratio | 1 | 2007 | 520 | 0.020 |
Why?
|
Neoplasms | 1 | 2014 | 22389 | 0.020 |
Why?
|
Piperazines | 1 | 2015 | 2552 | 0.020 |
Why?
|
Exercise | 1 | 2021 | 5947 | 0.010 |
Why?
|
Coronary Artery Disease | 1 | 2004 | 6566 | 0.010 |
Why?
|
Sodium Fluoride | 1 | 2005 | 67 | 0.010 |
Why?
|
Oxalates | 1 | 2005 | 99 | 0.010 |
Why?
|
Analgesics, Opioid | 1 | 2000 | 3836 | 0.010 |
Why?
|
Blood Preservation | 1 | 2005 | 169 | 0.010 |
Why?
|
Ambulatory Care | 1 | 2015 | 2784 | 0.010 |
Why?
|
Adenocarcinoma, Clear Cell | 1 | 2005 | 218 | 0.010 |
Why?
|
Survival Analysis | 1 | 2016 | 10117 | 0.010 |
Why?
|
Diet | 1 | 2021 | 8097 | 0.010 |
Why?
|
Potassium Channels | 1 | 2006 | 538 | 0.010 |
Why?
|
Hospitals | 1 | 2017 | 3905 | 0.010 |
Why?
|
Magnesium | 1 | 2007 | 816 | 0.010 |
Why?
|
Acidosis, Lactic | 1 | 2005 | 146 | 0.010 |
Why?
|
Blood Pressure | 1 | 2019 | 8541 | 0.010 |
Why?
|
Body Size | 1 | 2006 | 463 | 0.010 |
Why?
|
Receptors, Interleukin-4 | 1 | 2003 | 66 | 0.010 |
Why?
|
Respiratory Syncytial Virus Vaccines | 1 | 2003 | 37 | 0.010 |
Why?
|
Potassium | 1 | 2007 | 1319 | 0.010 |
Why?
|
Adenine | 1 | 2008 | 993 | 0.010 |
Why?
|
Vaccines, Inactivated | 1 | 2003 | 185 | 0.010 |
Why?
|
Viremia | 1 | 2005 | 725 | 0.010 |
Why?
|
Cytokines | 2 | 2010 | 7443 | 0.010 |
Why?
|
Injections, Subcutaneous | 1 | 2003 | 687 | 0.010 |
Why?
|
In Situ Nick-End Labeling | 1 | 2002 | 610 | 0.010 |
Why?
|
bcl-2-Associated X Protein | 1 | 2002 | 281 | 0.010 |
Why?
|
Perfusion | 1 | 2006 | 1402 | 0.010 |
Why?
|
Cerebral Infarction | 1 | 2006 | 975 | 0.010 |
Why?
|
Formaldehyde | 1 | 2003 | 361 | 0.010 |
Why?
|
Vaccinia virus | 1 | 2003 | 330 | 0.010 |
Why?
|
Vinblastine | 1 | 2002 | 488 | 0.010 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2006 | 1339 | 0.010 |
Why?
|
Brain Neoplasms | 1 | 2002 | 9197 | 0.010 |
Why?
|
Neutralization Tests | 1 | 2003 | 739 | 0.010 |
Why?
|
Antibody Specificity | 1 | 2003 | 1065 | 0.010 |
Why?
|
Species Specificity | 1 | 2005 | 2417 | 0.010 |
Why?
|
Cytoplasm | 1 | 2005 | 1500 | 0.010 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2002 | 427 | 0.010 |
Why?
|
Maximum Tolerated Dose | 1 | 2003 | 890 | 0.010 |
Why?
|
Interleukin-12 | 1 | 2003 | 577 | 0.010 |
Why?
|
Adenosine Triphosphate | 1 | 2007 | 2003 | 0.010 |
Why?
|
Diabetes Mellitus | 1 | 2019 | 5890 | 0.010 |
Why?
|
Caspase 3 | 1 | 2002 | 731 | 0.010 |
Why?
|
Immunohistochemistry | 2 | 2005 | 11117 | 0.010 |
Why?
|
Insulin | 2 | 2006 | 6608 | 0.010 |
Why?
|
Injections, Intravenous | 1 | 2002 | 1378 | 0.010 |
Why?
|
Glucose Tolerance Test | 1 | 2003 | 1183 | 0.010 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2002 | 631 | 0.010 |
Why?
|
Creatinine | 1 | 2005 | 1915 | 0.010 |
Why?
|
Caspases | 1 | 2002 | 880 | 0.010 |
Why?
|
Disease Susceptibility | 1 | 2006 | 1795 | 0.010 |
Why?
|
Microscopy, Electron | 1 | 2002 | 2559 | 0.010 |
Why?
|
Viral Envelope Proteins | 1 | 2003 | 641 | 0.010 |
Why?
|
Receptors, Opioid, mu | 1 | 2000 | 171 | 0.010 |
Why?
|
Interleukin-4 | 1 | 2003 | 1157 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2020 | 39405 | 0.010 |
Why?
|
Models, Biological | 1 | 2015 | 9494 | 0.010 |
Why?
|
Immunization | 1 | 2003 | 1219 | 0.010 |
Why?
|
Interferon-alpha | 1 | 2002 | 910 | 0.010 |
Why?
|
HIV Antibodies | 1 | 2005 | 1341 | 0.010 |
Why?
|
Dyslipidemias | 1 | 2005 | 873 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2013 | 14736 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2013 | 13019 | 0.010 |
Why?
|
Family Health | 1 | 2003 | 1255 | 0.010 |
Why?
|
Infusions, Intravenous | 1 | 2002 | 2226 | 0.010 |
Why?
|
Th2 Cells | 1 | 2003 | 1078 | 0.010 |
Why?
|
Cardiopulmonary Bypass | 1 | 2002 | 1097 | 0.010 |
Why?
|
Disease Progression | 1 | 2014 | 13646 | 0.010 |
Why?
|
Cisplatin | 1 | 2002 | 1661 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2016 | 26410 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2002 | 1408 | 0.010 |
Why?
|
Animals | 5 | 2007 | 169322 | 0.010 |
Why?
|
Rectum | 1 | 2000 | 900 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 2003 | 6228 | 0.010 |
Why?
|
Ventricular Function, Left | 1 | 2006 | 3942 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2002 | 6512 | 0.010 |
Why?
|
Swine | 1 | 2002 | 5993 | 0.010 |
Why?
|
Genotype | 1 | 2007 | 13038 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2002 | 6856 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2000 | 6238 | 0.010 |
Why?
|
Antibodies, Viral | 1 | 2003 | 3211 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2007 | 14783 | 0.010 |
Why?
|
Proto-Oncogene Proteins | 1 | 2002 | 4526 | 0.010 |
Why?
|
Cell Line | 1 | 2003 | 15593 | 0.000 |
Why?
|
Cell Line, Tumor | 1 | 2005 | 17132 | 0.000 |
Why?
|
Survival Rate | 1 | 2002 | 12870 | 0.000 |
Why?
|
Mice, Knockout | 1 | 2003 | 14481 | 0.000 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2007 | 16027 | 0.000 |
Why?
|
Prognosis | 1 | 2005 | 30020 | 0.000 |
Why?
|
Severity of Illness Index | 1 | 2002 | 15939 | 0.000 |
Why?
|
Inflammation | 1 | 2003 | 10863 | 0.000 |
Why?
|
Case-Control Studies | 1 | 2000 | 22292 | 0.000 |
Why?
|
Alzheimer Disease | 1 | 2003 | 8747 | 0.000 |
Why?
|
Cardiovascular Diseases | 1 | 2005 | 15652 | 0.000 |
Why?
|
Mice | 1 | 2003 | 82004 | 0.000 |
Why?
|
Magnetic Resonance Imaging | 1 | 2002 | 36849 | 0.000 |
Why?
|